Pulsed Thulium:YAG laser - What is the lithotripsy ablation efficiency for stone dust from human urinary stones? Results from an in vitro PEARLS study.
Ablation
Dust
Endourology
Kidney stones
Laser
Pulsed Thulium:YAG
Ureteroscopy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
20
07
2023
accepted:
10
09
2023
medline:
4
12
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
The novel pulsed thulium:yttrium-aluminum-garnet (p-Tm:YAG) laser was recently introduced. Current studies present promising p-Tm:YAG ablation efficiency, although all are based on non-human stone models or with unknown stone composition. The present study aimed to evaluate p-Tm:YAG ablation efficiency for stone dust from human urinary stones of known compositions. Calcium oxalate monohydrate (COM) and uric acid (UA) stones were subjected to lithotripsy in vitro using a p-Tm:YAG laser generator (Thulio®, Dornier MedTech GmbH, Germany). 200 J was applied at 0.1 J × 100 Hz, 0.4 J × 25 Hz or 2.0 J × 5 Hz (average 10W). Ablated stone dust mass was calculated from weight difference between pre-lithotripsy stone and post-lithotripsy fragments > 250 µm. Estimated ablated volume was calculated using prior known stone densities (COM: 2.04 mg/mm Mean ablation mass efficiency was 0.04, 0.06, 0.07 mg/J (COM) and 0.04, 0.05, 0.06 mg/J (UA) for each laser setting, respectively. This translated to 0.021, 0.029, 0.034 mm To our knowledge, this is the first study showing ablation efficiency of the p-Tm:YAG laser for stone dust from human urinary stones of known compositions. The p-Tm:YAG seems to ablate COM and UA equally well, with no statistically significant differences between differing laser settings.
Sections du résumé
BACKGROUND
BACKGROUND
The novel pulsed thulium:yttrium-aluminum-garnet (p-Tm:YAG) laser was recently introduced. Current studies present promising p-Tm:YAG ablation efficiency, although all are based on non-human stone models or with unknown stone composition. The present study aimed to evaluate p-Tm:YAG ablation efficiency for stone dust from human urinary stones of known compositions.
METHODS
METHODS
Calcium oxalate monohydrate (COM) and uric acid (UA) stones were subjected to lithotripsy in vitro using a p-Tm:YAG laser generator (Thulio®, Dornier MedTech GmbH, Germany). 200 J was applied at 0.1 J × 100 Hz, 0.4 J × 25 Hz or 2.0 J × 5 Hz (average 10W). Ablated stone dust mass was calculated from weight difference between pre-lithotripsy stone and post-lithotripsy fragments > 250 µm. Estimated ablated volume was calculated using prior known stone densities (COM: 2.04 mg/mm
RESULTS
RESULTS
Mean ablation mass efficiency was 0.04, 0.06, 0.07 mg/J (COM) and 0.04, 0.05, 0.06 mg/J (UA) for each laser setting, respectively. This translated to 0.021, 0.029, 0.034 mm
CONCLUSION
CONCLUSIONS
To our knowledge, this is the first study showing ablation efficiency of the p-Tm:YAG laser for stone dust from human urinary stones of known compositions. The p-Tm:YAG seems to ablate COM and UA equally well, with no statistically significant differences between differing laser settings.
Identifiants
pubmed: 37831156
doi: 10.1007/s00345-023-04640-4
pii: 10.1007/s00345-023-04640-4
pmc: PMC10693514
doi:
Substances chimiques
Thulium
8RKC5ATI4P
Calcium Oxalate
2612HC57YE
Holmium
W1XX32SQN1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3723-3730Informations de copyright
© 2023. The Author(s).
Références
World J Urol. 2023 Oct;41(10):2823-2831
pubmed: 37587366
Eur Urol Open Sci. 2022 Aug 19;44:20-22
pubmed: 36043189
J Endourol. 2021 Dec;35(S3):S14-S21
pubmed: 34910609
J Endourol. 2019 Jul;33(7):585-589
pubmed: 31084375
J Biomed Opt. 2016 Jan;21(1):18003
pubmed: 26784588
J Endourol. 2017 Jun;31(6):547-556
pubmed: 28095709
J Biomed Opt. 2017 Jan 1;22(1):18001
pubmed: 28301635
Eur Urol Open Sci. 2022 Aug 19;44:15-17
pubmed: 36043194
J Urol. 1998 Jan;159(1):17-23
pubmed: 9400428
Eur Urol Focus. 2023 Nov 6;:
pubmed: 37940392
BJU Int. 2020 Jul;126(1):159-167
pubmed: 32277557
J Endourol. 2021 Feb;35(2):221-225
pubmed: 32799650
World J Urol. 2021 Jun;39(6):1693-1698
pubmed: 32363450
J Urol. 2017 Sep;198(3):702-706
pubmed: 28442384
World J Urol. 2021 Mar;39(3):891-896
pubmed: 32462304
World J Urol. 2021 Dec;39(12):4459-4464
pubmed: 34392390
J Clin Med. 2021 Jul 30;10(15):
pubmed: 34362169
Urolithiasis. 2019 Aug;47(4):377-382
pubmed: 29947996
J Urol. 2023 Aug;210(2):323-330
pubmed: 37126223
Nat Rev Urol. 2018 Nov;15(11):653-654
pubmed: 29921906
J Biomed Opt. 2014 Dec;19(12):128001
pubmed: 25518001
World J Urol. 2023 Aug;41(8):2119-2125
pubmed: 37414942
J Endourol. 2018 Jan;32(1):1-6
pubmed: 29061070
World J Urol. 2022 Jul;40(7):1839-1844
pubmed: 35633401
J Endourol. 2022 Feb;36(2):259-265
pubmed: 34693738
J Urol. 2023 Feb;209(2):374-383
pubmed: 36621994
World J Urol. 2021 Jan;39(1):187-194
pubmed: 32270283
Urol Int. 2022;106(4):404-410
pubmed: 34134117
Urolithiasis. 2021 Oct;49(5):485-491
pubmed: 33655346
World J Urol. 2022 Jun;40(6):1529-1535
pubmed: 35246704
Int J Urol. 2021 Mar;28(3):261-265
pubmed: 33258271
World J Urol. 2020 Aug;38(8):1883-1894
pubmed: 30729311
World J Urol. 2022 Oct;40(10):2549-2553
pubmed: 35861860
World J Urol. 2020 Nov;38(11):2945-2953
pubmed: 31989208
J Urol. 1996 Sep;156(3):912-4
pubmed: 8709362
J Clin Med. 2023 Mar 29;12(7):
pubmed: 37048670
Urology. 2017 May;103:47-51
pubmed: 28089885
J Urol. 1993 Jul;150(1):239-45
pubmed: 8510264
World J Urol. 2021 Oct;39(10):3945-3950
pubmed: 33590280
World J Urol. 2015 Apr;33(4):463-9
pubmed: 25185524
J Endourol. 2020 Oct;34(10):1075-1081
pubmed: 32483996
Lasers Med Sci. 2022 Apr;37(3):2071-2078
pubmed: 34905141
Eur Urol Open Sci. 2022 Aug 19;44:27-29
pubmed: 36043190
J Endourol. 2020 Nov;34(11):1175-1179
pubmed: 32560595